BG
MDGL icon

BlackRock Group’s Madrigal Pharmaceuticals MDGL Stock Holding History

BlackRock Group’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-211
Closed -$2K – 3035
2016
Q1 		$2K Hold
211
– – ﹤0.01% 3044
2015
Q4 		$3K Hold
211
– – ﹤0.01% 2999
2015
Q3 		$13K Sell
211
-689
-77% -$49.7K ﹤0.01% 3012
2015
Q2 		$70K Buy
+900
New +$75.5K ﹤0.01% 2830

Other funds holding MDGL

CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

BlackRock Group's MDGL Position: Q2 2016 in Review

BlackRock Group sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2016, closing a stake of 211 shares — an estimated $2K sold.

BlackRock Group first reported a position in MDGL in Q2 2015 and held it in 4 quarters. The position peaked at $70K in Q2 2015. 55 funds tracked by Wall St. Rank hold MDGL as of Q2 2016.

  • BlackRock Group reported no remaining Madrigal Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • BlackRock Group sold 211 Madrigal Pharmaceuticals shares in Q2 2016, an estimated $2K.
  • BlackRock Group first reported a position in Madrigal Pharmaceuticals in Q2 2015 and held it in 4 quarters.
  • BlackRock Group's Madrigal Pharmaceuticals position peaked at $70K in Q2 2015.
  • 55 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2016.

Based on BlackRock Group's 13F filing for Q2 2016, filed 10 Aug 2016.